Nivolumab + Docetaxel + ADT in Metastatic Hormone Sensitive Prostate Cancer

Conditions:   Hormone Sensitive Prostate Cancer;   Prostate Adenocarcinoma;   Metastasis Prostate Adenocarcinoma Interventions:   Drug: Androgen Deprivation Therapy;   Drug: Nivolumab;   Drug: Docetaxel Sponsors:   Xiao X. Wei;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials